Victoria d'Este April 28, 2025 Today, the company shared that it has secured a $237 million Series C financing round, which pulled in various investors such as NVentures (part of NVIDIA), MAPS Capital (Mirae Asset Group), and Pictet Alternative Advisors.

Participating in this funding event were Generate:Biomedicines’ parent organization, Flagship Pioneering, and Fidelity Management & Research Company.

By employing advanced machine learning techniques, the company develops clinical protein complexes and enzymes, including antibodies that specifically target certain epitopes and functional antibodies that activate cell surface receptors.

With the new Series C funds, Generate:Biomedicines aims to enhance its generative AI pipeline, planning to file several Investigational New Drug (IND) applications in 2024 and initiate multiple clinical trials annually after that.

Jason Silvers, M.D., Chief Financial Officer of Generate:Biomedicines, expressed his excitement in a statement: 'We are delighted to have the backing of many investors who share our vision of leading a new frontier in programmable protein therapeutics powered by generative AI.'

Harnessing Generative AI to Optimize Drug Discovery

Utilizing an extensive dataset that encompasses natural protein structures and sequences alongside proprietary data, The Generate Platform—Generate:Biomedicines's advanced machine learning system—has unlocked key insights into how amino acid sequences dictate protein structure and function.

Silvers emphasized the company's commitment to significantly investing in The Generate Platform. Their plans focus on initiating new programs, advancing multiple projects through clinical trials, and strategically exploring additional collaborative opportunities that can enhance value.

The company asserts that its machine learning models meticulously examine hundreds of millions of known proteins to discern patterns and statistical correlations linking amino acid sequences with their structures and functions.

By implementing these statistical insights, they are able to create tailor-made protein therapeutics. These can range from short peptides to sophisticated antibodies, enzymes, gene therapies, and even entirely new protein entities.

Generate:Biomedicines claims to have a robust portfolio with 17 initiatives progressing through preclinical and clinical phases in sectors like oncology, immunology, and infectious diseases.

Since 2020, the firm has secured almost $700 million in equity funding, and since its Series B in 2021, it has:

• Commenced its first human trial for GB-0669, a monoclonal antibody targeting a crucial part of the SARS-CoV-2 spike protein. The outcomes of this trial are instrumental in addressing future pandemics and in improving treatment protocols for COVID variants.
• Set plans in motion for a Clinical Trial Application in early Q4 2023 for a monoclonal antibody targeting anti-TSLP for asthma, with clinical trials expected to rapidly follow.

"The company has made tremendous strides over the last five years, and I am optimistic this funding will allow us to envision a future where the development of drugs is no longer left to chance,” remarked Noubar Afeyan, Ph.D., Co-founder and Chairman of the Board at Generate:Biomedicines.

The rise of generative AI in the realm of drug discovery has sparked significant increases in funding for biotech companies utilizing this innovative technology. In July, Recursion, another biotech entity, secured an investment from NVIDIA as a private investment in public equity (PIPE). Know More Moreover, Recursion is set to partner with NVIDIA to fast-track the creation of AI foundational models aimed at drug discovery.

Please be reminded that the information on this page does not constitute legal, financial, investment, or any other form of advice. It is vital to only invest what you can afford to lose and to seek independent financial advice if you have any uncertainties. For more details, we recommend reviewing the terms and conditions along with the help and support pages provided by the issuer or advertiser. MetaversePost is committed to delivering precise, unbiased news, but market conditions may change without prior notice.